Physician profile
Fernanda Johnston
NPI 1104133065
$2,538.77
in general payments reported to CMS, 2019-2025
24 companies · $15.84 in 2025
The $15.84 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,523 · 2025: $15.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.59 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $257.09 | 2023 | Ingrezza, Ongentys |
| Lundbeck LLC | $210.16 | 2023 | Vyepti, Rexulti |
| Alkermes, INC. | $191.30 | 2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $166.77 | 2023 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $150.97 | 2023 | Rexulti, Nuedexta, Abilify Maintena |
| Pfizer INC. | $127.67 | 2023 | |
| Emd Serono, INC. | $110.38 | 2023 | Mavenclad |
| Eisai INC. | $81.99 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.11 | 2023 | Caplyta |
| Lilly USA, LLC | $74.58 | 2023 | Amyvid |
| Alexion Pharmaceuticals, INC. | $72.84 | 2023 | Ultomiris |
| Csl Behring | $71.69 | 2023 | Hizentra |
| Tg Therapeutics, INC. | $66.97 | 2023 | |
| Banner Life Sciences, LLC | $43.73 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.26 | 2023 | Trintellix |
| Neos Therapeutics, LP | $40.65 | 2023 | Adzenys Xr-Odt |
| Catalyst Pharmaceuticals, INC. | $33.95 | 2023 | Firdapse |
| Teva Pharmaceuticals USA, INC. | $32.45 | 2023 | Austedo Xr |
| Ucb, INC. | $25.20 | 2023 | |
| Argenx US, INC. | $24.44 | 2023 | |
| Novo Nordisk INC | $20.54 | 2023 | Wegovy |
| Avion Pharmaceuticals | $18.45 | 2023 | Dhivy |
| Upsher-Smith Laboratories LLC | $15.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernanda Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.